Introduction
Non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations is a prevalent subtype associated with specific targeted therapies. Despite initial responsiveness, resistance mechanisms often develop, necessitating novel treatment strategies. Recently, the combination of amivantamab, a bispecific antibody targeting EGFR and MET, with lazertinib, a third-generation EGFR tyrosine kinase inhibitor, has emerged as a promising approach, especially in untreated cases.
